Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Emerging concepts, hot topics, and open questions in today's pancreatic cancer research.

Biochimica et biophysica acta. Reviews on cancer·2026

Same author

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

Cancer genetics·2026

Same author

A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Same author

Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.

Nature communications·2026

Same author

Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis.

Nature communications·2025

Same author

Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Molecular changes in pancreatic cancer.

Malte Buchholz¹, Thomas M Gress

¹Klinik f. Innere Medizin, SP Gastroenterologie, Universitätsklinikum Marburg, Baldingerstrasse 35043 Marburg, Germany. malte.buchholz@staff.uni-marburg.de

Expert Review of Anticancer Therapy

|October 16, 2009

Summary

Pancreatic cancer involves numerous genetic changes, but the functional impact of most alterations remains unknown. Further research is needed to identify key cell types and premalignant lesion behaviors in pancreatic cancer development.

More Related Videos

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Area of Science:

Oncology
Genetics
Molecular Biology

Background:

Pancreatic cancer is a complex human malignancy driven by genetic alterations.
Thousands of DNA, mRNA, miRNA, and protein alterations are linked to pancreatic cancer.
While some key mutations are well-studied, the functional significance of most alterations is unclear.

Purpose of the Study:

To highlight the knowledge gaps in understanding pancreatic cancer's genetic landscape.
To emphasize the need for research into the functional roles of genetic alterations.
To address uncertainties regarding cell transformation and premalignant lesions in pancreatic cancer.

Main Methods:

Review of existing literature on pancreatic cancer genetics.
Analysis of reported DNA, mRNA, miRNA, and protein alterations.
Examination of studies on gatekeeper mutations and their significance.

Main Results:

Extensive data exists for some pancreatic cancer-associated alterations, particularly gatekeeper mutations.
Functional data is lacking for the majority of identified genetic alterations.
Uncertainty persists regarding the cell of origin and the nature of premalignant lesions.

Conclusions:

Despite extensive research, significant gaps remain in understanding the functional impact of genetic alterations in pancreatic cancer.
Further investigation is crucial to elucidate the cell of origin and the progression of premalignant lesions.
A comprehensive understanding of these factors is essential for advancing pancreatic cancer diagnosis and treatment.